Pacira BioSciences Lowers FY23 Net Product Sales From $550M-$560M To $530M-$540M
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences has revised its FY23 net product sales forecast downwards from $550M-$560M to $530M-$540M.
November 02, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacira BioSciences has lowered its FY23 net product sales forecast, which may negatively impact investor sentiment and the company's stock price.
Pacira BioSciences has lowered its FY23 net product sales forecast. This could be perceived negatively by investors as it indicates potential future revenue decline, which could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100